Received Sep 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
possible redness at the injection site; possible swelling at the injection site; This non-serious case was reported by a nurse via sales rep and described the occurrence of injection site erythema in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On 29-JUL-2025, the patient received Menveo. On 01-AUG-2025, 3 days after receiving Menveo, the patient experienced injection site erythema (Verbatim: possible redness at the injection site) and injection site swelling (Verbatim: possible swelling at the injection site). The outcome of the injection site erythema and injection site swelling were unknown. It was unknown if the reporter considered the injection site erythema and injection site swelling to be related to Menveo. It was unknown if the company considered the injection site erythema and injection site swelling to be related to Menveo. Additional Information: GSK receipt date: 08-AUG-2025 The pharmacy buyer called to report about a potential reaction following a Menveo vaccination. She mentioned possible redness and swelling at the injection site; Sender's Comments: US-GSK-US2025102722:Diffrent patient